These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38322949)

  • 1. Could internal limiting membrane peeling before Voretigen neparvovec-ryzl subretinal injection prevent focal chorioretinal atrophy?
    Dormegny L; Studer F; Sauer A; Ballonzoli L; Speeg-Schatz C; Bourcier T; Dollfus H; Gaucher D
    Heliyon; 2024 Feb; 10(3):e25154. PubMed ID: 38322949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis.
    Gange WS; Sisk RA; Besirli CG; Lee TC; Havunjian M; Schwartz H; Borchert M; Sengillo JD; Mendoza C; Berrocal AM; Nagiel A
    Ophthalmol Retina; 2022 Jan; 6(1):58-64. PubMed ID: 33838313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification and Growth Rate of Chorioretinal Atrophy after Voretigene Neparvovec-Rzyl for RPE65-Mediated Retinal Degeneration.
    Bommakanti N; Young BK; Sisk RA; Berrocal AM; Duncan JL; Bakall B; Mathias MT; Ahmed I; Chorfi S; Comander J; Nagiel A; Besirli CG
    Ophthalmol Retina; 2024 Jan; 8(1):42-48. PubMed ID: 37660736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting.
    Lorenz B; Künzel SH; Preising MN; Scholz JP; Chang P; Holz FG; Herrmann P
    Ophthalmology; 2024 Feb; 131(2):161-178. PubMed ID: 37704110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Full-field Scotopic Threshold Improvement after Voretigene Neparvovec-rzyl Treatment Correlates with Chorioretinal Atrophy.
    Stingl K; Stingl K; Schwartz H; Reid MW; Kempf M; Dimopoulos S; Kortuem F; Borchert MS; Lee TC; Nagiel A
    Ophthalmology; 2023 Jul; 130(7):764-770. PubMed ID: 36822437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chorioretinal atrophy following voretigene neparvovec despite the presence of fundus autofluorescence.
    Kolesnikova M; Lima de Carvalho JR; Parmann R; Kim AH; Mahajan VB; Tsang SH; Sparrow JR
    Mol Genet Genomic Med; 2022 Nov; 10(11):e2038. PubMed ID: 36225124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perimacular Atrophy Following Voretigene Neparvovec-Rzyl Treatment in the Setting of Previous Contralateral Eye Treatment With a Different Viral Vector.
    Ku CA; Igelman AD; Huang SJ; Bailey ST; Lauer AK; Duncan JL; Weleber RG; Yang P; Pennesi ME
    Transl Vis Sci Technol; 2024 Jun; 13(6):11. PubMed ID: 38888288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis.
    Deng C; Zhao PY; Branham K; Schlegel D; Fahim AT; Jayasundera TK; Khan N; Besirli CG
    Graefes Arch Clin Exp Ophthalmol; 2022 May; 260(5):1543-1550. PubMed ID: 35001204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Therapy with Voretigene Neparvovec Improves Vision and Partially Restores Electrophysiological Function in Pre-School Children with Leber Congenital Amaurosis.
    Gerhardt MJ; Priglinger CS; Rudolph G; Hufendiek K; Framme C; Jägle H; Salchow DJ; Anschütz A; Michalakis S; Priglinger SG
    Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation after Voretigene Neparvovec Administration in Patients with RPE65-Related Retinal Dystrophy.
    Kessel L; Christensen UC; Klemp K
    Ophthalmology; 2022 Nov; 129(11):1287-1293. PubMed ID: 35760216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The first gene therapy for
    Ferraz Sallum JM; Godoy J; Kondo A; Kutner JM; Vasconcelos H; Maia A
    Ophthalmic Genet; 2022 Aug; 43(4):550-554. PubMed ID: 35416119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Objective Outcomes to Evaluate Voretigene Neparvovec Treatment Effects in Clinical Practice.
    Melillo P; Testa F; Di Iorio V; Karali M; Citro A; Della Corte M; Rossi S; Banfi S; Simonelli F
    Ophthalmol Retina; 2024 Jul; 8(7):688-698. PubMed ID: 38295874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pars plana vitrectomy with internal limiting membrane flap versus pars plana vitrectomy with conventional internal limiting membrane peeling for large macular hole.
    Ghoraba H; Rittiphairoj T; Akhavanrezayat A; Karaca I; Matsumiya W; Pham B; Mishra K; Yasar C; Mobasserian A; Abdelkarem AA; Nguyen QD
    Cochrane Database Syst Rev; 2023 Aug; 8(8):CD015031. PubMed ID: 37548231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optic nerve atrophy after vitrectomy with indocyanine green-assisted internal limiting membrane peeling in diffuse diabetic macular edema. Adverse effect of ICG-assisted ILM peeling.
    Ando F; Yasui O; Hirose H; Ohba N
    Graefes Arch Clin Exp Ophthalmol; 2004 Dec; 242(12):995-9. PubMed ID: 15592868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary silicone oil tamponade and internal limiting membrane peeling for retinal detachment due to macular hole in highly myopic eyes with chorioretinal atrophy.
    Hong N; Huang BS; Tong JP
    BMC Ophthalmol; 2015 Nov; 15():165. PubMed ID: 26560878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-Term Outcomes of the First in Vivo Gene Therapy for RPE65-Mediated Retinitis Pigmentosa.
    Kwak JJ; Kim HR; Byeon SH
    Yonsei Med J; 2022 Jul; 63(7):701-705. PubMed ID: 35748082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INTERNAL LIMITING MEMBRANE PEELING VERSUS INVERTED FLAP TECHNIQUE FOR TREATMENT OF FULL-THICKNESS MACULAR HOLES: A COMPARATIVE STUDY IN A LARGE SERIES OF PATIENTS.
    Rizzo S; Tartaro R; Barca F; Caporossi T; Bacherini D; Giansanti F
    Retina; 2018 Sep; 38 Suppl 1():S73-S78. PubMed ID: 29232338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large Idiopathic Macular Hole Surgery: Remodelling of Outer Retinal Layers after Traditional Internal Limiting Membrane Peeling or Inverted Flap Technique.
    Bottoni F; Parrulli S; Mete M; D'Agostino I; Cereda M; Cigada M; Maggio E; Maraone G; Iacovello D; Bottega E; Staurenghi G; Pertile G
    Ophthalmologica; 2020; 243(5):334-341. PubMed ID: 31940651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fovea-Sparing versus Standard Internal Limiting Membrane Peeling for Myopic Traction Maculopathy: A Study of 102 Consecutive Cases.
    Shiraki N; Wakabayashi T; Ikuno Y; Matsumura N; Sato S; Sakaguchi H; Nishida K
    Ophthalmol Retina; 2020 Dec; 4(12):1170-1180. PubMed ID: 32470651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec.
    Reichel FF; Seitz I; Wozar F; Dimopoulos S; Jung R; Kempf M; Kohl S; Kortüm FC; Ott S; Pohl L; Stingl K; Bartz-Schmidt KU; Stingl K; Fischer MD
    Br J Ophthalmol; 2023 Sep; 107(9):1331-1335. PubMed ID: 35609955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.